Cargando…

Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study

BACKGROUND: Dotinurad is a novel uricosuric drug in Japan with selective and potent urate transporter 1 (URAT1) inhibitory activity. This study aims to evaluate the efficacy and safety of dotinurad in hyperuricemic patients with type 2 diabetic kidney disease by comparing serum levels of urate and p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osonoi, Takeshi, Saito, Miyoko, Hosoya, Mitsuru, Douguchi, Satako, Ofuchi, Kensuke, Katoh, Makoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875127/ https://www.ncbi.nlm.nih.gov/pubmed/36714585 http://dx.doi.org/10.3389/fendo.2022.1042061

Ejemplares similares

Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial
por: Osonoi, Takeshi, et al.
Publicado: (2023)

A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout
por: Hosoya, Tatsuo, et al.
Publicado: (2020)

Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia
por: Osonoi, Takeshi, et al.
Publicado: (2023)

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study
por: Osonoi, Takeshi, et al.
Publicado: (2020)

A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients
por: Hosoya, Tatsuo, et al.
Publicado: (2020)

Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study
por: Hosoya, Tatsuo, et al.
Publicado: (2019)

Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor
por: Fukase, Hiroyuki, et al.
Publicado: (2019)

Comparative study of a novel selective urate reabsorption inhibitor “dotinurad” among patient groups with different stages of renal dysfunction
por: Takahashi, Toshinari, et al.
Publicado: (2021)

Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia
por: Kuriyama, Satoru
Publicado: (2019)

Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study
por: Hosoya, Tatsuo, et al.
Publicado: (2019)

Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
por: Tanaka, Atsushi, et al.
Publicado: (2023)

Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment
por: Kumagai, Yuji, et al.
Publicado: (2019)

Canagliflozin Increases Postprandial Total Glucagon-Like Peptide 1 Levels in the Absence of α-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A Single-Arm, Non-randomized, Open-Label Study
por: Osonoi, Takeshi, et al.
Publicado: (2019)

Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout
por: Hosoya, Tatsuo, et al.
Publicado: (2019)

The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor
por: Okui, Daisuke, et al.
Publicado: (2019)

Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study
por: Hosoya, Tatsuo, et al.
Publicado: (2020)

A drug–drug interaction study of a novel, selective urate reabsorption inhibitor dotinurad and the non-steroidal anti-inflammatory drug oxaprozin in healthy adult males
por: Furihata, Kenichi, et al.
Publicado: (2020)

Comparison of the Effects of Allopurinol and Febuxostat on the Values of Triglycerides in Hyperuricemic Patients
por: Ziga-Smajic, Nermina, et al.
Publicado: (2020)

Efficacy and Safety of Dotinurad in Hyperuricemic Patients With or Without Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Iqbal, Ayman, et al.
Publicado: (2021)

URAT1 is expressed in cardiomyocytes and dotinurad attenuates the development of diet-induced metabolic heart disease
por: Tanaka, Yoshiro, et al.
Publicado: (2023)

A Possible Exquisite Crosstalk of Urate Transporter 1 With Other Urate Transporters for Chronic Kidney Disease and Cardiovascular Disease Induced by Dotinurad
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Four‐year sequential nerve conduction changes since first visit in Japanese patients with early type 2 diabetes
por: Kobori, Mariko, et al.
Publicado: (2016)

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout
por: Terkeltaub, Robert, et al.
Publicado: (2019)

A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients
por: Pichholiya, Meenu, et al.
Publicado: (2016)

Febuxostat attenuates ER stress mediated kidney injury in a rat model of hyperuricemic nephropathy
por: He, Li, et al.
Publicado: (2017)

Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis
por: Zhang, Shengzhao, et al.
Publicado: (2021)

Dendrobium officinalis Six Nostrum Promotes Intestinal Urate Underexcretion via Regulations of Urate Transporter Proteins in Hyperuricemic Rats
por: Ge, Hongzhang, et al.
Publicado: (2023)

Effect of febuxostat on blood pressure in hyperuricemic patients: A protocol for a systematic review and meta-analysis
por: Yao, Jia, et al.
Publicado: (2020)

Astragaloside IV improves the pharmacokinetics of febuxostat in rats with hyperuricemic nephropathy by regulating urea metabolism in gut microbiota
por: Zhao, Zhen Xiong, et al.
Publicado: (2022)

Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout
por: Hosoya, Tatsuo, et al.
Publicado: (2014)

S100 Genes are Highly Expressed in Peripheral Leukocytes of Type 2 Diabetes Mellitus Patients Treated with Dietary Therapy
por: Kondo, Shinnosuke, et al.
Publicado: (2021)

Total saponins from Discorea nipponica makino ameliorate urate excretion in hyperuricemic rats
por: Zhou, Qi, et al.
Publicado: (2015)

Urate crystal deposition in hyperuricemic children: a dual energy computed tomography study
por: Ying, Qianqian, et al.
Publicado: (2021)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
por: Jackson, Robert L, et al.
Publicado: (2012)

SLC2A9 (GLUT9) mediates urate reabsorption in the mouse kidney
por: Auberson, Muriel, et al.
Publicado: (2018)

Anti-Hyperuricemic Effects of Astaxanthin by Regulating Xanthine Oxidase, Adenosine Deaminase and Urate Transporters in Rats
por: Le, Yanzuo, et al.
Publicado: (2020)

A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout
por: Zhang, Fengchun, et al.
Publicado: (2019)

Is urate crystal precipitation a predictor of cardiovascular risk in hyperuricemic patients? A Danish cohort study
por: Larsen, Kasper Søltoft, et al.
Publicado: (2015)

Production Inhibition and Excretion Promotion of Urate by Fucoidan from Laminaria japonica in Adenine-Induced Hyperuricemic Mice
por: Zhang, Dayan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0sskevnof1beoqfdvagtuovh5t